Pasithea Therapeutics Corp. (KTTA) intrinsic value & 10-year financials
Pasithea Therapeutics Corp. (KTTA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.42
- Market cap
- $3.0M
- Revenue (FY2025)
- —
- Revenue growth (6-yr CAGR)
- 3130.4%
- ROIC (10-yr avg)
- -87.6%
- Free cash flow (FY2025)
- —
KTTA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$20.4M | -$2.91 | — | — | -58.4% |
| FY2024 | — | -$13.9M | -$12.69 | — | — | -72.8% |
| FY2023 | — | -$16.0M | -$0.42 | -$12.8M | — | -159.4% |
| FY2022 | $486.6K | -$13.9M | -$0.53 | -$14.9M | -3045.1% | -139.2% |
| FY2021 | $15.1K | -$2.2M | -$0.21 | -$3.2M | -29925.7% | -8.4% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Pasithea Therapeutics Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Pasithea Therapeutics Corp. has historically struggled to out-earn its cost of capital, averaging just -56.1% ROIC.
Pasithea Therapeutics Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Pasithea Therapeutics Corp. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-96.66 per share.